Application of arglabin in preventing, relieving or / and treating sepsis cardiomyopathy
By using Agrabin to inhibit inflammation-related proteins and reduce cardiomyocyte apoptosis, the problem of unclear efficacy and major side effects of septic cardiomyopathy in the prior art has been solved, and the improvement of heart function and prevention of septic cardiomyopathy has been achieved. Effect.
Patent Information
- Application Number
- CN202411421791.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-12
- Publication Date
- 2024-12-06
AI Technical Summary
The existing drugs for treating septic cardiomyopathy are unclear in efficacy, have great side effects, lack specificity, and are unable to effectively inhibit the occurrence and development of septic cardiomyopathy. There is insufficient clinical data, and it is urgently necessary to develop new preventive and therapeutic drugs.
Agrabin as the main active ingredient is used to reduce cardiomyocyte apoptosis and improve cardiac contraction function by inhibiting the expression of inflammation-related proteins such as IL-1β and TNF-α, and to reduce cardiomyopathy. drug.
Agrabin can improve the heart contraction function of mice with septic cardiomyopathy, reduce cardiac dysfunction, reduce the expression of inflammation-related proteins, and inhibit cardiomyopathy, thereby effectively preventing and treating septic cardiomyopathy.
Smart Images

Figure HDA0005081016800000011 
Figure HDA0005081016800000012 
Figure HDA0005081016800000021
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of biomedicine, and specifically relates to the application of arglabin in preventing, alleviating or / and treating septic cardiomyopathy. Background Art
[0002] Sepsis is characterized by multiple organ failure caused by toxins produced by pathogenic microorganisms. Sepsis-induced cardiomyopathy, also known as sepsis-induced cardiomyopathy (SIC), refers to sepsis combined with cardiovascular dysfunction, which is manifested by uncontrolled inflammatory response to severe infection and subsequent cascade inflammatory response, cardiac systolic dysfunction and myocardial depression. Septic cardiomyopathy accounts for 18-65% of all sepsis complications, and the mortality rate of cardiomyopathy (cardiac systolic dysfunction) caused by it is 80%. The pathogenesis of SIC is not fully understood, and it is currently believed to be multifactorial, mainly involving myocardial inhibitory factors, inflammatory response, oxidative stress, mitochondrial dysfunction and other aspects. Among them, myocardial inhibitory factors cause myocardial dysfunction by inhibiting myocardial contractility and reducing cardiac output, while inflammatory response causes direct damage to myocardial cells by activating multiple inflammatory mediators and cytokines. Oxidative stress and mitochondrial dysfunction further aggravate myocardial cell damage and apoptosis. Currently, the high-risk factors for SIC mainly include: age, underlying heart disease, severity of infection, degree of systemic inflammatory response, etc. The severity of SIC is closely related to the prognosis of sepsis patients.
[0003] The clinical manifestations of septic cardiomyopathy are diverse. Mild cases may have no obvious symptoms, while severe cases may develop serious complications such as heart failure and arrhythmia. At present, the diagnosis of septic cardiomyopathy is mainly based on the patient's clinical manifestations, electrocardiogram examinations, laboratory tests, etc. The treatment of SIC mainly includes active anti-infection, appropriate fluid resuscitation and effective organ function support. The treatment measures include the use of vasoconstrictors, positive inotropes (such as dobutamine, milrinone, levosimend), frequency control (β-blockers, ivabradine), statins, immunotherapy and mechanical circulatory support. Despite the progress in timely diagnosis and effective treatment, sepsis and septic cardiomyopathy are still the main causes of death. However, so far, there is no specific therapeutic drug with clear efficacy and few side effects in this field. The existing guidelines for drug treatment of SIC are only at the level of expert experience, lack of high-quality clinical data, and no clear evidence to suggest that the occurrence and development of SIC can be inhibited. Therefore, there is an urgent need to develop new drugs for preventing the occurrence or delaying the progression of septic cardiomyopathy in this field.
[0004] With the progress of medicine and health care, the treatment strategy of SIC has been continuously optimized, but its etiology and specific pathogenesis are still unclear. At present, most studies believe that the pathogenesis of SIC is mainly related to the following aspects: (1) Genetics: Genetic composition determines the body's susceptibility and resistance to severe infectious diseases. Related studies have found that the human TLR4 gene has at least two genetic polymorphisms: Asp299Gly (substitution of aspartic acid and glycine at position 299) and Thr399Ile (substitution of threonine and isoleucine at position 399). This genetic polymorphism is closely related to the susceptibility of patients with sepsis and may be a risk factor for whether infected patients develop sepsis. (2) Inflammation: The occurrence of inflammation plays a vital role in the occurrence and development of SIC. The pathophysiological process of SIC is considered to be an acute uncontrolled inflammatory response and a subsequent cascade of inflammatory responses. Various types of cytokines such as TNF-α, IL-1β, IL-6, intercellular and vascular cell adhesion molecule-1 (I / VCAM-1), macrophage migration inhibitory factor (MIF), human high mobility group protein B1 (HMGB-1), complement C5a, lysosomes, platelet activating factor (PAF), and endothelin-1 (ET-1) are involved in the inflammatory response of SIC. (3) Energy metabolism disorder: In sepsis patients and animal models, lipid aggregation and glycogen deposition in damaged myocardial cells increase lactate uptake, decrease ketone bodies, free fatty acids and glucose uptake, significantly decrease mitochondrial Na+K+-ATPase and Ca2+-ATPase activities, mitochondrial ultrastructure destruction, insufficient energy supply to myocardial cells, and significantly reduce myocardial contractility. (4) Cardiomyocyte apoptosis: Cardiomyocyte apoptosis can be triggered under conditions such as inflammation, ischemia, hypoxia, and stress. Studies have shown that during the onset of sepsis, the level of aspartate-specific cysteine protease-3 (caspase-3), an effector of apoptosis, in the CLP-induced sepsis rat model was 2 times higher than that in the normal control group, indicating an increase in myocardial cell apoptosis. (5) Myocardial renin-angiotensin (RAS) system: The RAS system exerts its biological effects through the binding of angiotensin II (Ang II) to the AT1 receptor. The myocardial RAS system participates in the regulation of local myocardial vascular tension and blood flow, increases the release of catecholamines from sympathetic nerve endings, and regulates myocardial contractile function. Currently, more and more studies believe that the activation of the myocardial RAS system plays an extremely important role in myocardial damage in sepsis, and may cooperate with inflammatory mediators such as TNF-α to promote the occurrence of myocardial damage. Sepsis myocardial damage may be a pathophysiological process in which multiple factors participate together, but the above-mentioned different mechanisms will affect each other, forming a vicious cycle and promoting the occurrence of SIC.
[0005] Arglabin, also known as parthenolide derivative, has a molecular formula of C15H18O3 and is a sesquiterpene gamma lactone. Arglabin has been approved for clinical trials in many countries and is prescribed as an anticancer drug for breast cancer, lung cancer, and ovarian cancer either as a monotherapy or in combination with other chemotherapeutic drugs. In addition to its classical anti-tumor effects, arglabin also exerts significant anti-inflammatory effects in various cell types. For example, it can exert important anti-inflammatory activity by inhibiting the NLRP3 inflammasome. In addition, arglabin also inhibits the expression of cytokines such as IFN-γ, IL-2, IL-1β, IL-18, and TNF-α, causing the macrophage phenotype to change from pro-inflammatory M1 to anti-inflammatory M2. Recently, arglabin has been clearly shown to have anti-inflammatory effects in chronic inflammatory cardiovascular diseases such as atherosclerosis. The research and drug development of aglabin is currently a cutting-edge field of research at home and abroad. A series of studies have shown the broad prospects of aglabin as a drug target in clinical drug development. However, there are no research reports on its application in improving and treating septic cardiomyopathy. It is urgent to clarify the therapeutic effect of aglabin in acute cardiac dysfunction caused by sepsis. Summary of the invention
[0006] In view of the problems and shortcomings in the prior art, the purpose of the present invention is to provide a use of arglabin in preventing, alleviating and / or treating septic cardiomyopathy.
[0007] To achieve the purpose of the invention, the technical solution adopted by the present invention is as follows: The first aspect of the present invention provides the use of arglabin in preparing a product for preventing, alleviating or / and treating septic cardiomyopathy.
[0008] The second aspect of the present invention provides the use of arglabin in the preparation of a product for improving the cardiac contractile function of patients with septic cardiomyopathy.
[0009] The third aspect of the present invention provides the use of arglabin in the preparation of a product for preventing, reducing or / and inhibiting myocardial cell apoptosis caused by septic cardiomyopathy.
[0010] The fourth aspect of the present invention provides the use of arglabin in the preparation of a drug for inhibiting or reducing the expression level of inflammation-related proteins in septic cardiomyopathy.
[0011] According to the above application, preferably, the inflammation-related proteins include IL-1β and TNF-α.
[0012] According to the above application, preferably, the product is a medicine, and the medicine contains arglabin and pharmaceutically acceptable excipients.
[0013] According to the above application, preferably, the dosage form of the drug is granules, capsules, tablets, powders, oral liquids or emulsions.
[0014] A fifth aspect of the present invention provides a drug, which contains arglabin and a pharmaceutically acceptable excipient, and is used to prevent, alleviate and / or treat septic cardiomyopathy, or to improve the cardiac contractile function of patients with septic cardiomyopathy, or to inhibit or reduce the expression level of inflammation-related proteins in septic cardiomyopathy.
[0015] According to the above-mentioned medicine, preferably, the dosage form of the medicine is granules, capsules, tablets, powders, oral liquids or emulsions.
[0016] Compared with the prior art, the present invention has the following positive and beneficial effects: The present invention discovers for the first time that aglabin can improve the cardiac contractile function of LPS-induced septic cardiomyopathy in mice and alleviate the cardiac dysfunction of LPS-induced septic cardiomyopathy in mice; moreover, cell experiments also show that aglabin can inhibit the apoptosis of myocardial cells by reducing the expression levels of inflammatory-related proteins (IL-1β and TNF-α) in septic cardiomyopathy, thereby inhibiting the occurrence, development and treatment of septic cardiomyopathy. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] Figure 1 The results of cardiac ultrasound detection of mice in the Control group, LPS+Vehicle group, and LPS+Arglabin group; A is a representative picture of cardiac ultrasound of mice in each group, B is the statistical result of left ventricular ejection fraction (LVEF) of mice in each group, and C is the statistical result of shortening fraction (LVFS) of mice in each group; Figure 2 The results of TUNEL staining experiments, where A is a representative picture of TUNNEL staining of primary mouse cardiomyocytes, where fluorescence indicates apoptotic cardiomyocytes, and B is the quantitative statistical result of TUNEL staining; Figure 3 These are the ELISA test results of inflammation-related proteins IL-1β and TNF-α; wherein A is the test result of IL-1β, and B is the test result of TNF-α. DETAILED DESCRIPTION
[0018] In order to enable those skilled in the art to more clearly understand the technical solution of the present invention, the technical solution of the present invention will be described in detail below in conjunction with specific embodiments.
[0019] The following detailed descriptions are exemplary and are intended to provide further explanation of the present invention. Unless otherwise specified, all technical and scientific terms used herein have the same meanings as those commonly understood by those skilled in the art to which the present invention belongs.
[0020] It should be noted that the terms used herein are only for describing specific embodiments and are not intended to limit exemplary embodiments according to the present invention. As used herein, unless the context clearly indicates otherwise, the singular form is also intended to include the plural form. In addition, it should be understood that when the terms "comprise" and / or "include" are used in this specification, it indicates the presence of features, steps, operations, components and / or combinations thereof.
[0021] The experimental methods in the following examples without specifying specific conditions all adopt conventional techniques in the art or follow the conditions recommended by the manufacturers; the reagents or instruments used without specifying the manufacturers are all conventional products that can be obtained commercially.
[0022] The molecular biochemical reagents used in the following examples are as follows: Arglabin, lipopolysaccharides (LPS), phosphate-buffered saline (PBS), IL-1β ELISA kit, TNF-α ELISA kit, etc. were purchased from Sangon Biotechnology (China), chemiluminescent HRP substrate ECL luminescent liquid was from Millipore (USA), isoflurane was from Runan Beite (China), and Tunel kit was purchased from Roche.
[0023] Example 1: Effect of Aglabin on Cardiac Function in Mice with Sepsis-induced Cardiomyopathy 1. Experimental animals and culture conditions: 10-12 week old C57BL / 6 male mice were kept in a special bacteria-free device with constant humidity and temperature, adequate food and water, and a 12-hour light and 12-hour dark cycle.
[0024] 2. Experimental grouping and treatment: C57BL / 6 male mice were divided into three groups: Control group, LPS+Vehicle group, and LPS+Arglabin group, with 20 mice in each group.
[0025] The mice in the LPS+Arglabin group were intraperitoneally injected with arglabin solution at a dose of 20 mg arglabin / kg body weight, once a day for 5 consecutive days; the arglabin solution was prepared by dissolving arglabin in a DMSO-corn oil mixed solvent (the DMSO-corn oil mixed solvent was prepared by mixing DMSO and corn oil at a volume ratio of 1:9). The mice in the Control group and the LPS+Vehicle group were intraperitoneally injected with a comparable dose of DMSO-corn oil mixed solvent, once a day for 5 consecutive days.
[0026] One hour after the last intraperitoneal injection of DMSO-corn oil mixed solvent, mice in the LPS+Vehicle group were intraperitoneally injected with lipopolysaccharide (LPS) solution at a dose of 10 mg LPS / kg body weight. Six hours after the injection, the mouse septic cardiomyopathy model was successfully established. One hour after the last intraperitoneal injection of arglabin solution, mice in the LPS+Arglabin group were intraperitoneally injected with lipopolysaccharide (LPS) solution at a dose of 10 mg LPS / kg body weight. One hour after the last intraperitoneal injection of DMSO-corn oil mixed solvent, mice in the Control group were intraperitoneally injected with the same dose of normal saline (sodium chloride with a mass percentage concentration of 0.9%). Among them, the LPS solution was prepared by dissolving LPS in normal saline (sodium chloride solution with a mass percentage concentration of 0.9%).
[0027] 3. Mouse heart ultrasound detection: Six hours after the LPS+Vehicle group and the LPS+Arglabin group were intraperitoneally injected with lipopolysaccharide (LPS) solution, the mice in the Control group, LPS+Arglabin group, and LPS+Vehicle group were subjected to cardiac ultrasound examination. The specific operation of cardiac ultrasound examination was as follows: the mice were anesthetized with 2% isoflurane inhalation and fixed in a supine position on an ultrasound examination table with a built-in heating function. The hair in the precordial area was first removed with a depilatory cream. The parasternal long axis section was collected on the chest wall using the VisualSonics VeVo2100 ultrasound diagnostic instrument and a 30MHz high-frequency probe, and the electrocardiogram was recorded and the heart rate was measured. Two-dimensional ultrasound section images were obtained at the level of the papillary muscle under the mitral valve in the parasternal left ventricular short axis section, and the left ventricular ejection fraction (LVEF) and shortening fraction (LVFS) were measured. The instrument parameter settings for the examination of mice in each group were kept the same, and the image acquisition and calculation were performed by the same person. The average value of 4-5 different cardiac cycles was selected for each measurement index.
[0028] The results of mouse heart ultrasound examination were as follows Figure 1 shown.
[0029] Depend on Figure 1 It can be seen that compared with the Control group, the cardiac contractile function of mice with septic cardiomyopathy induced by intraperitoneal injection of LPS deteriorated, and the cardiac contractile function of mice with septic cardiomyopathy was improved after administration of aglabin. This shows that the cardiac function of mice with septic cardiomyopathy was significantly impaired after intraperitoneal injection of LPS; aglabin can improve the cardiac function of mice with septic cardiomyopathy and alleviate the cardiac dysfunction of mice with septic cardiomyopathy induced by LPS.
[0030] Example 2: Effects of Aglabin on Mouse Cardiomyocytes 1. Experimental cells: The hearts of C57BL / 6J background mice were taken and primary cardiomyocytes were extracted.
[0031] 2. Experimental grouping, treatment and detection methods: (1) Experimental grouping and treatment: The extracted primary mouse cardiomyocytes were divided into three groups, namely PBS+Vehicle group, LPS+Vehicle group, and LPS+Arglabin group. The following solutions were prepared for use: Arglabin solution was prepared by dissolving Arglabin in DMSO solvent, and the final concentration of Arglabin solution in cell experiments was 3 mmol / L; LPS solution was prepared by dissolving LPS in isotonic PBS solution, and the final concentration of LPS solution in cell experiments was 1 μg / mL.
[0032] Each group was treated as follows: LPS+Arglabin group: Arglabin solution (final concentration 3 μmol / L) was added to the cardiomyocytes for 4 hours, and then LPS solution (final concentration 1 μg / mL) was added for 4 hours; LPS+Vehicle group: an equivalent amount of DMSO solvent was added to the cardiomyocytes for 4 hours, and then LPS solution (final concentration 1 μg / mL) was added for another 4 hours; PBS+Vehicle group: A comparable amount of DMSO solvent was added to the cardiomyocytes for 4 hours, and then isotonic PBS solution was added for another 4 hours as a control.
[0033] TUNEL staining was performed on the cardiomyocytes of the PBS+Vehicle group, LPS+Vehicle group, and LPS+Arglabin group after the above treatment.
[0034] (2) Detection method: 1) TUNEL staining TUNEL staining was performed on the cardiomyocytes of the PBS+Vehicle group, LPS+Vehicle group, and LPS+Arglabin group after the above treatment.
[0035] The specific operation of TUNEL staining is as follows: A. Equipment preparation: a) Deionized water: Make sure to use deionized water to avoid ions interfering with the reaction. b) Enzyme label preparation: If the DNase enzyme label used has been opened or has been stored for a long time, it should be treated with oxidative heat enthalpy overnight before use.
[0036] B. Sample fixation: Take the cell sample and place it in an ion-deficient buffer, making sure the sample is completely covered by the liquid. Add 4% paraformaldehyde (or other cell or tissue fixative) and fix it at room temperature for 10-15 minutes. Rinse the sample 3 times with cold PBS, 10 minutes each time.
[0037] C. Permeabilize the sample: Place the fixed cells or tissue in a solution containing 0.5% Triton X-100 in PBS and permeabilize for 30 minutes at room temperature. Rinse the sample again with cold PBS for 3 times, 10 minutes each time. Use DNase enzyme labeling to detect DNA cleavage in the sample.
[0038] D. TUNEL reaction: Prepare enough TUNEL reaction solution and keep it on ice when frozen according to the experimental needs. Restore the sample to PBS, add enough TUNEL reaction solution to ensure that the sample is completely infiltrated and try to avoid bubbles. Incubate at 37℃ for 1-2 hours.
[0039] E. Reaction termination: Move the specimen to a refrigerator and rinse it with PBS for 3 times at room temperature, 10 minutes each time. Rinse the specimen again with buffer for 3 times, 10 minutes each time.
[0040] F. Visualization and analysis: Add fluorescence inhibitors or dyes such as DAPI and detect using a fluorescence microscope.
[0041] 2) ELISA to detect inflammation-related protein levels: The levels of inflammation-related proteins IL-1β and TNF-α in myocardial cells of the PBS+Vehicle group, LPS+Vehicle group, and LPS+Arglabin group after the above treatment were detected by IL-1β ELISA kit (purchased from R&Dsystem, USA, catalog number SMLB00C) and TNF-α ELISA kit (purchased from R&Dsystem, USA, catalog number PMTA00B). The specific experimental operations are as follows: A. Preparation: Prepare various solutions: a) Cell culture supernatant: Centrifuge at 4000rpm for 20min to remove cell particles and polymers, and store the supernatant below -20℃ to avoid repeated freezing and thawing. b) Kit: Take out the kit from the refrigerator 30min in advance and equilibrate to room temperature. c) Washing buffer: Heat the concentrated washing solution taken out of the refrigerator and shake it gently to completely dissolve the crystals before preparing. Dilute the concentrated washing solution with double distilled water (1:20). d) Standard: Add 1.0mL of standard / specimen diluent to the lyophilized standard, wait for it to be completely dissolved, let it stand for 15 minutes to mix (concentration is 2000pg / mL), and then dilute as needed.
[0042] B. Determine the number of strips required based on the number of samples to be tested and the number of standards, and add one well as a blank control well. Add the specimen and different concentrations of standards (100 μL / well) to the corresponding wells (only add standard / sample diluent to the zero well), seal the reaction wells with sealing tape, and incubate at 37°C for 90 minutes (except the blank control well).
[0043] C. Wash the plate 4 times: shake off all liquid in the wells, add 350 μL of washing solution to each well, let it stand for 30 seconds, then shake off all liquid and pat dry on thick absorbent paper.
[0044] D. Add biotinylated antibody working solution (100 μL / well). Seal the reaction wells with sealing tape, incubate at 37°C for 60 minutes (except for the blank control wells), and then wash the plate 4 times.
[0045] E. Add enzyme conjugate working solution (100 μL / well), seal the reaction wells with sealing tape, incubate at 37°C for 30 minutes (except blank control wells), and then wash the plate 4 times.
[0046] F. Add 100 μL / well of color developer, protect from light, and incubate at 37°C for 10-20 minutes.
[0047] G. Add 100 μL / well of stop solution, mix well and measure OD450 value immediately (within 5 minutes).
[0048] 3. Experimental results: The results of TUNEL staining experiments are shown in Figure 2 shown.
[0049] Depend on Figure 2 It can be seen that the apoptosis of cardiomyocytes in mice increased after LPS stimulation, and decreased after administration of aglabin, which indicates that aglabin can inhibit the apoptosis of cardiomyocytes caused by septic cardiomyopathy.
[0050] The ELISA test results of inflammation-related proteins IL-1β and TNF-α are as follows Figure 3 shown.
[0051] Depend on Figure 3 As shown in Figure A, LPS stimulation can significantly increase the IL-1β protein content in cardiomyocytes, and administration of aglabin can significantly reduce the IL1β protein content in primary mouse cardiomyocytes stimulated by LPS. Figure 3 As shown in Figure B, LPS stimulation can significantly increase the content of TNF-α protein in cardiomyocytes, and administration of aglabin can significantly reduce the content of TNF-α protein in primary mouse cardiomyocytes stimulated by LPS. This shows that LPS stimulation can increase the expression level of inflammation in cardiomyocytes, while aglabin can inhibit the expression level of inflammation-related proteins.
[0052] The above experimental results show that aglabin can reduce the expression levels of inflammation-related proteins IL-1β and TNF-α in cardiomyocytes and inhibit cardiomyocyte apoptosis caused by septic cardiomyopathy; moreover, aglabin can improve the cardiac contractile function of LPS-induced septic cardiomyopathy in mice and reduce the cardiac dysfunction of LPS-induced septic cardiomyopathy in mice. Therefore, aglabin can be used to prevent, alleviate or / and treat septic cardiomyopathy, and inhibit the occurrence and development of septic cardiomyopathy.
[0053] In summary, the present invention effectively overcomes the deficiencies in the prior art and has a high industrial utilization value. The above embodiments serve to illustrate the substantial content of the present invention, but do not limit the protection scope of the present invention. Those skilled in the art should understand that the technical solution of the present invention can be modified or replaced by equivalents without departing from the essence and protection scope of the technical solution of the present invention.
Claims
1. Use of aglabin in the preparation of products for preventing, alleviating or / and treating septic cardiomyopathy.
2. The use of aglabin in the preparation of products for improving cardiac contractile function in patients with septic cardiomyopathy.
3. Use of arglabin in the preparation of products for preventing, reducing or / and inhibiting myocardial cell apoptosis caused by septic cardiomyopathy.
4. The use of aglabin in the preparation of drugs for inhibiting or reducing the expression level of inflammation-related proteins in septic cardiomyopathy.
5. The use according to claim 4, characterized in that: The inflammation-related proteins include IL-1β and TNF-α.
6. The use according to any one of claims 1 to 5, characterized in that: The product is a medicine, which contains arglabin and pharmaceutically acceptable excipients.
7. The use according to claim 6, characterized in that: The dosage form of the medicine is granules, capsules, tablets, powders, oral liquid or emulsion.
8. A drug, characterized in that The drug contains arglabin and pharmaceutically acceptable excipients, and is used for preventing, alleviating and / or treating septic cardiomyopathy, or for improving the cardiac contractile function of patients with septic cardiomyopathy, or for inhibiting or reducing the expression level of inflammation-related proteins in septic cardiomyopathy.
9. The drug according to claim 8, characterized in that The dosage form of the medicine is granules, capsules, tablets, powders, oral liquid or emulsion.
